Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma in Early COVID-19 Infection
NCT06084351Phase 3Withdrawn
- Sponsor
- Larkin Community Hospital
- Start
- May 2020
- Primary completion
- Oct 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Convalescent Plasma Arm with Standard of Care Arm (2 arms). Primary endpoint: Time to clinical improvement within 28 days. Planned start May 2020; status: withdrawn.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06084351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06084351.